AstraZeneca stock steadies near $158 as latest quarter shows revenue growth

AstraZeneca PLC (ISIN US6549022043) stock closed at about $158.10 on the New York Stock Exchange on August 12, 2026, leaving the pharma heavyweight in a tight range even as its most recent quarterly results show revenue and profit growth.

Quarterly earnings show solid growth

According to data compiled by Tradingkey, AstraZeneca reported revenue of 15.38 billion in its latest reported quarter, labeled FY2026Q2, representing a 6.41 percent increase year over year from the comparable period.

The same overview indicates that AstraZeneca generated net income of 2.51 billion in that FY2026Q2 period, underscoring that profit is growing broadly in line with the top line rather than being pressured despite ongoing investment in research and development.

Analyst consensus and upside potential

Per the NYSE-focused coverage on MarketBeat, AstraZeneca shares last traded at $158.14 on August 12, 2026, with the platform citing an average analyst rating score of 2.73, based on a mix of buy, hold, and a small number of sell recommendations.

The same MarketBeat summary puts the consensus price target at $211.00 for AstraZeneca, implying roughly 33.4 percent upside from the $158.14 level as of August 12, 2026, which is broadly consistent with the 34.04 percent upside indicated by the separate Tradingkey stock analysis page that lists a target price of 217.027.

Key product focus in oncology

One of AstraZeneca PLC's flagship oncology therapies is Tagrisso, a targeted treatment for certain types of non small cell lung cancer that has become a central part of the company oncology portfolio and a meaningful contributor to revenue in recent years.

Shares and recent price action

Based on the Tradingkey quote page for AstraZeneca PLC, the stock closed at $158.10 on August 12, 2026, down 0.41 percent on the day, with the move captured as a drop of 0.650 in the closing quote snapshot for the NYSE session ending at 4:00 p.m. Eastern Time.